Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin/Semaglutide - Novo Nordisk

Drug Profile

Dapagliflozin/Semaglutide - Novo Nordisk

Alternative Names: NN 9917; SemaDapa FDC; SemaDapa FDC - Novo Nordisk; Semaglutide/Dapagliflozin - Novo Nordisk

Latest Information Update: 23 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihypercalcaemics; Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucagon-like peptides; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics; Vascular disorder therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 13 Apr 2023 Novo Nordisk completes a phase I trial in Type 2 diabetes mellitus (In Volunteers) in Germany (PO) (EudraCT2022-500007-52-00) (NCT05429593)
  • 23 Jun 2022 Preclinical trials in Unspecified in USA (PO) (NCT05429593)
  • 22 Jun 2022 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Germany (PO) (NCT05429593) (EudraCT2022-500007-52-00)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top